Emory Alzheimer's Disease Research Center

摘要/摘要：临床核心 临床核心的主要目标是支持和加强Goizueta阿尔茨海默氏症的研究工作 埃默里疾病研究中心(ADRC)将推进尖端研究，以识别新的生物标志物和 治疗目标，同时减少AD研究中的种族差异。临床核心在以下方面发挥着核心作用 Goizueta ADRC通过吸引不同的研究参与者和推动反映该中心总体 主题。为了实现这些目标，临床核心制定了良好的招聘、跟踪、 确定并保留一批纵向研究参与者，并有效协调各项活动 并与亚洲发展研究中心的其他部门和外部合作伙伴共享数据。在本资助期内， 临床核心建立了一个纵向生物标记物集合，以支持高优先级的多中心研究 项目，包括阿尔茨海默病加速医学伙伴关系(AMP-AD)和阿尔茨海默病分子机制 阿尔茨海默病的血管病因(M20VE-AD)。LBC的成功开发导致了一个具有竞争力的补充 建立一个生物标志核心，它将继续作为ADRC更新的核心组成部分。此外，在 在当前的周期中，我们成功地实现了增加UDS队列多样性的雄心勃勃的目标，通过注册一个 新加入的非裔美国人和高加索人人数相等。这一成功支持了该公司的建立 少数群体参与核心(MEC)。此次更新的具体目标是：1)建立和维护 不同的具有良好特征的研究参与者队列，以支持当前ADRD研究的优先事项；2) 通过协调样本收集和临床表型鉴定程序来促进生物标记物发现工作 跨多个相关项目和群组；以及3)扩大和整合ADRD的活动，包括 血管认知障碍与路易体疾病。实现这些具体目标将推动 《国家阿尔茨海默病项目法》(NAPA)中确定的优先事项和NIH ADRD的建议 研究峰会，并最终将导致有效的诊断工具和治疗个人的痛苦 患有阿尔茨海默病和相关疾病。

SUMMARY/ABSTRACT: CLINICAL CORE The primary goals of the Clinical Core are to support and enhance research efforts of the Goizueta Alzheimer’s Disease Research Center (ADRC) at Emory to advance cutting-edge research to identify novel biomarkers and therapeutic targets while reducing racial disparities in AD research. The Clinical Core plays a central role in the Goizueta ADRC by engaging diverse research participants and driving activities that reflect the Center’s overall themes. To accomplish these goals, the Clinical Core has well-established processes to recruit, track, characterize, and retain a cohort of longitudinal research participants and to effectively coordinate activities and share data with other components of the ADRC and external partners. In the current funding period, the Clinical Core established a Longitudinal Biomarker Collection to support high-priority multicenter research projects, including the Accelerating Medicine Partnership for AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD). Successful development of the LBC led to a competitive supplement to establish a Biomarker Core which will continue as a Core component in the ADRC renewal. Also, during the current cycle, we succeeded in our ambitious goal for increasing the diversity of our UDS cohort by enrolling an equal number of new African-American and Caucasian participants. This success supported the establishment of a Minority Engagement Core (MEC). Specific Aims for this renewal are to 1) Establish and maintain a diverse cohort of well-characterized research participants to support priorities in current ADRD research; 2) Advance biomarker discovery efforts by harmonizing procedures for sample collection and clinical phenotyping across multiple related projects and cohorts; and 3) Expand and integrate activities in ADRD, including vascular cognitive impairment and Lewy body diseases. Achieving these Specific Aims will advance the priorities identified in the National Alzheimer’s Project Act (NAPA) and recommendations from the NIH ADRD Research Summits, and will ultimately lead to effective diagnostic tools and treatments for individuals suffering from AD and related disorders.